Erlotinib in the treatment of advanced squamous cell NSCLC
| Autor: | Jan Krejčí, František Salajka, Marek Minarik, Jindrich Finek, Libor Havel, Miloš Pešek, L Benesova, Michal Hrnčiarik, Ondřej Fiala, Zbyněk Bortlíček |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Polymerase Chain Reaction Erlotinib Hydrochloride Carcinoma Non-Small-Cell Lung Internal medicine medicine Carcinoma Humans Epidermal growth factor receptor Adverse effect Protein Kinase Inhibitors neoplasms Survival rate Aged Neoplasm Staging Retrospective Studies biology business.industry DNA Neoplasm Middle Aged Prognosis medicine.disease Rash respiratory tract diseases ErbB Receptors Survival Rate Clinical trial Mutation Carcinoma Squamous Cell Quinazolines biology.protein Female Erlotinib medicine.symptom business Follow-Up Studies medicine.drug |
| Zdroj: | Neoplasma. 60:676-682 |
| ISSN: | 1338-4317 |
| Popis: | Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib’s efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage (IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|